Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Plans already afoot for 125m lateral flow tests pa for RTC and Mologic. Any other product contracts will require further expansion
Safy, calm down, it was your post that mentioned AVCT! Id id not suggest any of the things you are complaining about.
AVCT are looking for more manufacturers. It is reported that they have been in talks with ODX. Whether anything comes of it I have no idea,.
I also don't think you talk **** (whatever that means) and as I said although its a race I am pretty sure the market will be big enough for a huge variety of tests from a similar number of providers and manufacturers. (I also have ODX shares, not that it matters).
As an aside I have no idea why there is always such vitriol between these small pharma BB's.... but I am sure that's for another day.
Twatcher, agree. They've said they have orders for what they've made and the increased production is to fill demand. Once they hit capacity and confirm orders, this will be unstoppable. So good time to buy imo and even better position for ODX to be in. Sp in bargain territory but not for too much longer. The tech transfer with Mologic is also a massive deal.
I'll vouch for Safy....definitely doesn't say anything unless he's researched it thoroughly.
Why does everything have to be hijacked by Avacta members here. Cant even have a conversation with our board members without someone ramping Avacta.
"Taken a hit over capacity, I think we should have been at 200k in Sept, then Oct, and now confirmed for Nov"
The graph in the presentation Has Oct @ 200K, and Nov @300K
"For me the main news is the CE mark of the Mologic test which hopefully should happen early November, its truly Game On from that point. "
The main news for me is that they are definitely planning a ramp up to 800K tests a month by Jan, and have plans for 2M by April. IMO don't have that level of planning without really good vision for orders. Prior to last night, we were unaware of this aggressive rampup.
wyndrum,
i dont really care about whether Avacta get that approval or not. Give it a rest PLEASE. There is an Avacta board for your post.
All i know is that Mologic and ODX are partners, I also know for an ABSOLUTE fact that Mologic are ahead of Avacta in the test development. No amount of posts will convince me otherwise. I have done my research, i have spoke to people.
If you think i talk ****, then go and ask anyone on the GDR board about my credentials.
Safy turn the telescope around... Without AVCT, they have nothing to manufacture. If AVCT do get approval and its as good as has been hinted at, then every govt in the world may well t want that test. And I imagine ODX will be manufacturing it as well?
The market is so huge there will be I am sure there will be many collaborations between what perhaps were deemed competitors only 12 months ago.
The thing is BBI and Abingdon is they had nothing to lose by working with Avacta. They have been desperately trying to get other products on board to add to their portfolio and use up their capacity. You never want to rely on one product no matter how good it is. Omega achieved this early with Mologic thanks to Colin King. When negotiating something like the UK RTC contract, if you only have 1 product and are reliant on 1 customer it puts you in a weak position. If Avacta test fails they have spare capacity that can be offered up elsewhere.
Look at the Sona drop today. It shows the risk of being reliant on 1 product that is not yet approved. Omega have a hedged portfolio of lateral flow and lab antibody and Elisa tests for self and professional use. Our risk is being managed extremely well and arguably we have the best portfolio of products out there including the best antibody test in the world, the only triple antibody lateral flow tests, and soon one of the first lateral flow antigen test. The value of what Omega have is far beyond todays mcap.
So given that these tests sell for peanuts.... dont BBI have Avacta over a barrel because Avacta dont actually have any manufacturing capacity?
Safy - "I have a question here, Mologic will CE mark test before TT to us, how are Avacta doing a TT to BBI without a CE? Answers from ODX holders only."
The TT on Avacta is from developer to lead manufacturer. Cytiva will not be manufacturing the test therefore cannot CE mark it. Part of CE marking is validating production lines. Mologic are developer and manufacturer therefore they will CE mark themselves.
So one thing that is positive is that it feels the reset button has been hit.
We've had a huge drop from 127 to 74...
Taken a hit for the Finncap report
Taken a hit on the RTC profit expectations
Taken a hit from Deek (apology isnt enough, the damage had been done)
REACT study, i expected a hit there too, but i think that if you ready it with an objective mind it tells us what we knew anyway, Antibodies wane over time, so in my simplistic mind, if an Antibody test picks up antibodies, then you are immune, that much they cannot deny, so is the Antibody test useful? yes i feel it is, did the media paint an alternative picture? yes they did.
Taken a hit over capacity, I think we should have been at 200k in Sept, then Oct, and now confirmed for Nov
Taken a hit for being overvalued in some eyes
Taken a hit for Walbrook POOR PR
And im sure there are other things too. Bottom line this is where we are, I dont think they can throw more bad news at us as everything is priced in.
For me the main news is the CE mark of the Mologic test which hopefully should happen early November, its truly Game On from that point. The RTC antibody tests are now merely an addition and not the main player, just looking at the tweet today, the graph clearly illustrates the demand. I dont think we need Colin to tell us this, but if they double up shifts and the value of the LFT is recognised then its going to be a pretty good December/January.
Mologic CE Mark the test early next month, which could be as early as end of next week.
ODX start the tech transfer, and best case in 4 weeks we could be ready to CE mark under our own brand.
I have a question here, Mologic will CE mark test before TT to us, how are Avacta doing a TT to BBI without a CE? Answers from ODX holders only.
But as i wrote above, the main thing for me is that Mologic CE mark the test. That would be conclusive proof that the test is ready and working and is coming to us.